Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma
about
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Update on pancreatic neuroendocrine tumors.Requiem for the term 'carcinoid tumour' in the gastrointestinal tract?Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathwayDaily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategyAntiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasEffect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.A rare gastric neuroendocrine carcinoma coexisting with Brunner's gland adenoma: A case report.Antitumor effects of somatostatin analogs in neuroendocrine tumors.Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect.Pancreatic Neuroendocrine Tumors: an Update.Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesSomatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Octreotide LAR: safety and tolerability issues.Gastrointestinal neuroendocrine tumors.Future perspectives on neuroendocrine tumors.Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.Therapy innovation for the treatment of pancreatic neuroendocrine tumors.Treatment options for unresectable neuroendocrine liver metastases.Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.Medical treatment of gastroenteropancreatic neuroendocrine tumors.Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.Nasopharyngeal carcinoid tumor: successful therapy for a tumor in a unique location.Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
P2860
Q28290833-589159E7-8814-482F-AF65-FC3C4E1B62F1Q30364864-9C7E6AC7-3F35-4D95-B322-8C72AE281AC8Q33753449-6E10FB45-2B1B-467E-87F8-D0E99BEE4F5EQ33782024-C6B24FC3-2C2B-4011-955A-48E4772BD233Q34453043-0CF0FE04-D8B4-4096-8832-2994C378D043Q34770091-1290EB62-BD39-449D-BA6B-6804440D9788Q34887795-83A5A6F5-5533-4A6A-9615-3790E485BA20Q34965132-65E7673E-2797-4FE2-AAB8-1440901A57A5Q34978826-081930F2-0335-4DA4-9D03-BAB206DFE051Q34992833-DDF0AD36-5ACF-4117-838B-43FC8585699CQ35001777-1F000160-1F43-4A95-AAE8-BD8B9B9ED4E1Q35550939-652EDB2B-5E1E-4117-B04F-8021A6BC86DCQ35669138-C0F9813C-AE51-4698-9B33-30D0A0207900Q35760798-2541584E-894E-463F-8794-9BA30C690885Q35837124-0460B67B-7407-4A45-9F78-70C853025E50Q35944519-5DAD88FF-3A38-4E00-9CAB-8F6C4686B9DDQ36051476-9AF699D1-434E-4336-88E3-5BEC0374B096Q36230918-BF5EA9D1-0AB0-4E7D-ADF5-744AC865B89CQ36400062-9F7469AC-6A83-4334-A558-91521676481DQ36882123-BC0056C7-D017-4FCD-8A96-A76E2E154751Q37056120-48E9B550-C4DD-4351-9D4A-A8DE316998FCQ37125550-B5B7B3BE-4DDD-4CE8-9BB6-DAD7F01BE2B7Q37483944-8C12F042-5673-4458-B222-3B022A07D48BQ37564373-ACB21EDB-A089-458E-BE0A-43DA63E5A4A0Q37649647-925EB22F-0D57-4BC1-A757-68E26700DCA1Q37799954-3662D321-F48C-4A13-B322-1BF3DF562E21Q37843819-27A1B37E-2E47-4759-8034-6E4C57EB6B84Q37875054-64092895-0CE9-41FD-967E-9E9190A43C53Q37988905-E340CF3B-5A00-49D4-A016-157DA183E435Q38014498-B4ED3E78-05B0-4BF0-9223-8A89FF91E911Q38035844-0D5CA33E-EBD6-4D0C-8FDF-0C00D5D02044Q38096476-FE6DDEE9-0A11-43A1-AF63-9ADB3C557177Q38711101-75719C82-5382-42F9-81DC-5A092865D601Q38755167-D938ED03-B73E-4A17-9415-48E091C4823EQ39217510-2A6B628B-934C-4EA4-B277-C5D106EE258DQ39254045-87733226-92C6-40A4-9C3A-82F738E4483BQ42469904-E1B28DBD-F390-4B59-B915-3C0773EB590EQ46106273-5822C7C9-32F8-4CD7-9D00-AE49AEDFCBD5Q47724538-797E06D7-858C-4E87-B505-CD9EB17C85D2
P2860
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma
description
im Dezember 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 19 December 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2005
@uk
name
Long-term clinical outcome of ...... pancreatic endocrine carcinoma
@en
Long-term clinical outcome of ...... pancreatic endocrine carcinoma
@nl
type
label
Long-term clinical outcome of ...... pancreatic endocrine carcinoma
@en
Long-term clinical outcome of ...... pancreatic endocrine carcinoma
@nl
prefLabel
Long-term clinical outcome of ...... pancreatic endocrine carcinoma
@en
Long-term clinical outcome of ...... pancreatic endocrine carcinoma
@nl
P2093
P50
P356
P1433
P1476
Long-term clinical outcome of ...... pancreatic endocrine carcinoma
@en
P2093
E Iannicelli
G Delle Fave
M Di Fonzo
M S Cattaruzza
P Pederzoli
P304
P356
10.1093/ANNONC/MDJ113
P577
2005-12-19T00:00:00Z